Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Athira Pharma ( (ATHA) ) is now available.
On September 10, 2025, Athira Pharma announced a 10-for-1 reverse stock split of its common stock, effective September 17, 2025, to comply with Nasdaq’s $1.00 minimum bid price requirement. The reverse stock split, approved by stockholders in May 2025, aims to enhance marketability and liquidity, potentially attracting a broader range of investors.
The most recent analyst rating on (ATHA) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Athira Pharma stock, see the ATHA Stock Forecast page.
Spark’s Take on ATHA Stock
According to Spark, TipRanks’ AI Analyst, ATHA is a Underperform.
Athira Pharma’s stock is weighed down by its financial performance, typical of an early-stage biotech firm with no revenue and high cash burn. Technical indicators show a lack of positive momentum, while valuation metrics reflect unprofitability. The stock’s prospects heavily depend on future product development and commercialization.
To see Spark’s full report on ATHA stock, click here.
More about Athira Pharma
Athira Pharma, Inc., based in the Seattle, Washington area, is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. The company aims to alter the course of neurological diseases by advancing its pipeline of drug candidates that modulate the neurotrophic HGF system.
Average Trading Volume: 183,867
Technical Sentiment Signal: Sell
Current Market Cap: $15.03M
See more insights into ATHA stock on TipRanks’ Stock Analysis page.